Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00449527 · ClinicalTrials.gov registry record · Phase 3
A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 123
- Enrollment target
NCT00449527 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 123 participants.
The verdict
NCT00449527, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 123 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) using a 1 week recall period versus a 1 day recall period.
Interventions
- DRUG Budesonide HFA pMDI
- DRUG Budesonide/formoterol pMDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00449527
The ClinicalTrials.gov registry entry for NCT00449527 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Budesonide HFA pMDI is the first listed.
NCT00449527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00449527 about?
NCT00449527 is a clinical study titled "A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects". The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) using a 1 week recall period versus a 1 day recall period.
What is the current status of trial NCT00449527?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2007-03. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00449527?
The interventions under investigation include: Budesonide HFA pMDI (DRUG), Budesonide/formoterol pMDI (DRUG).
Who is sponsoring clinical trial NCT00449527?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.